vsportÌåÓýƽ̨

À´Ô´£ºÂÉʦº¯Ä£°å £¬×÷Õߣº £¬£º

ÚÀ £¬ÎÒ¸úÄ㽲࣠£¬ÕâÌõ·ÕÕ¾ÉÓе㽲¾¿µÄ¡£

×î½üÄã¿Ï¶¨ÌýÈ˽²¡¸Ö麣Á«»¨Â·ÁíÓÐÃÃÃÃÂ𡹠£¬¸ãµÃÂù¶àÈ˶¼ºÃÆæ £¬¾õµÃÊDz»ÊÇÓÐɶ×ÓÏ¡ÆæµÄ¡£ÄãÏþµÃ £¬ÕâÃû×ÖÌýÆð¾ÍÂùÓÐÎÕÐáâ© £¬ÄÄ×ÓÏþµÃÕæÒªÈ¥¹ä £¬¿ÉÄÜࣲ»ÊÇÄãÏëµÄí¥×Ó¼òµ¥¡£ÎÒÄêÇá×ÓÄÇ¿­ £¬¶ÔÕâÌõ·ҲÓеãºÃÆæ £¬¿ËÁ˼¸»Ø £¬»¹ÕæÊÇÓеãÃŵÀ¡£

Õâ¸öÂï £¬Ö麣Á«»¨Â·Æäʵ²»ÊÇɶ×ÓºÜÈÈÄֵĴó½Ö £¬ËüÊÇÌõÏï×Ó £¬²ØÔÚ¹ðÁÖÀϳÇÇøµÄ±ß±ß¿©¡£Ïï×ÓͷСµê×ÓÂù¶à £¬ÓÐЩ»¹ÂùÓÐζµÀ £¬ºÃ±ÈÄǸöÂôÁ¹·ÛµÄС̯ £¬Î¶µÀÀÏÕý×ÚÁË £¬Ò»Íë϶ǵֵÃÉÏÈýÆ·ÍõµÄÒ»¶Ù·Ûà£~¿ÉÊÇÂï £¬Õâ¸öµØ·½Ò²Óеã˵·¨ £¬¹äµÄʱºò±ðÌ«ËæÒâ¡£

Ïï×ÓµÄÃŵÀ £¬ÄãÏþµÃࣣ¿

ÎÒ¸úÄ㽲࣠£¬Ö麣Á«»¨Â·ÒÔǰÊǸöÂùÓйÊʵĵط½¡£ÎÒÒ¯Ò¯¸úÎÒ½²¹ý £¬ÔçЩÄêÕâ¿­ÊÇһЩÊÖÒÕÈ˾ۼ¯µÄµØ·½ £¬²Ã·ìÆÌ¡¢ÐÞЬ̯¡¢ÁíÓиöÓͲè� £¬ÄǸöÓͲè�µÄÀϰåÊǸöÀÏÊÖ £¬²èÅݵúÃÏã £¬ÁÚÀïÁÚ¾Ó¶¼°®¿ËËûÄÇ¿­·¢»áñ²¡£

²»¹ý¿© £¬ÕâÌõ·ØÊºó±äµÃÓеãÅÓ´ó¡£ÄãÏþµÃ £¬Ïï×ÓÀïÍ·ÓÐЩµê×ÓÍâò¿´ÆðÆÕͨ £¬Êµ¼ÊÉϲØ×ŵã¹Å×С£ÓÐЩÊÇ×öÉúÒâµÄ £¬ÓÐЩÂï £¬ËµÇ·ºÃ¡£ÄêÇá×ÓÎÒÓÐÒ»´Î¿ËÁ«»¨Â· £¬¿´µ½Ò»¼ÒÀí·¢µê £¬Ãû×ÖÂùÆÕͨ £¬µ«ÃÅ¿ÚÄǵƹ⡢ÁíÓÐÄǸö×°ÐÞ £¬Õ¦¿´¶¼²»Ïñ´¿´âÀí·¢µÄµØ·½¡£ØÊºóÌýÈ˽² £¬ÄÇ¿­ÓÐЩµê×ÓÊÇרÃÅ×ö¡°ÌØÊâЧÀÍ¡±µÄ¡£Äã½²ÊÇûÊÇ£¿ÕâÃû×ÖÌýÆðÇåÇå°×°× £¬Êµ¼ÊÉÏÒªÁôµãÐÄ¡£

Ïà¹ØÍ¼Æ¬
Ïà¹ØÍ¼Æ¬ ÚÀ £¬ÎÒ͵͵¸æËßÄã £¬ÄãÒªÕæ¿ËÖ麣Á«»¨Â··¢ñ² £¬×îºÃÊǰ×ÌìÈ¥ £¬ÍíÉϾͱðÂÒ¹äÁË¡£°×Ììµê×Ó¿ªÃÅ×öÕý¾­ÉúÒâ £¬Á¹·Û̯¡¢ÓͲè�ÕâЩÂù²»´í£»ÍíÉÏÂï £¬ÓÐЩµê×ӵƹâÒ»ÁÁ £¬¿© £¬Äã¾ÍÏþµÃÁË £¬²»ÊÇÆÕͨµê×Ó¡£ÀϹðÁÖ¶¼ÏþµÃÕâ¸ö¹æÔò¡£

×îºóÒ»¾äࣣºÏï×ÓµÄ÷ÈÁ¦ £¬ÕÕ¾ÉÒªÃ÷°×Æ·¡£

ÕÕÎÒ¿´À´à£ £¬Ö麣Á«»¨Â·ÆäʵÂùÓйðÁÖζµÀµÄ¡£ËüµÄÏï×ÓССÍäÍä £¬ÏñÍõ³ÇÀïÍ·µÄ· £¬²Ø×ŵãÀÏÊÖÒպ͹ÊÊ £¬µ«Í¬Ê±Ò²ÓеãÈÃÈËÃþ²»Í¸µÄ¹Å×С£ÄãÒªÊÇÐÄϸ £¬ÂýÂý¹ä £¬ÄÇЩÀϵê×ÓÕæµÄÊÇÄܸøÄ㾪ϲ£»ÄãÒªÊÇÐļ± £¬¾õµÃÄÄ×Ó¶¼ºÃÆæ £¬ÄǾÍÓпÉÄÜÔÔ¸úÍ·¡£¸ü×Ó½² £¬Ïï×ÓÀïµÄ÷ÈÁ¦ÊDzØ×ÅµÄ £¬Ã÷°×ÂýÂýÆ· £¬²ÅÏþµÃËüµÄºÃ¡£


ÚÀ £¬ÄÇÖ麣Á«»¨Â·¾¿¾¹ÁíÓÐɶ×Ӻõط½£¿

ÎÒ¸úÄ㽲࣠£¬¿ËÄÇ¿­µÄ»° £¬ÓÐÒ»¼ÒÁ¹·Û̯ÊÇÒ»¶¨Òª³¢µÄ £¬Ãû×ֽС°°¢»¨Á¹·Û¡± £¬Î¶µÀÕæµÎÊÇÇåˬÓÖËíµÀ£»ÁíÓÐÒ»¼ÒÓͲè� £¬ÀÏÅÆ×Ó £¬½Ð¡°Á«»¨ÀÏÓͲ衱 £¬ÓͲèÅäÕ¨ôÎôÎ £¬ÕæµÎÊÇÏãÍêÁË¡£¼Ç×Å £¬°×Ìì¹ä £¬±ðÍíÉÏÂÒÅÜ࣡£

±êÇ©£º

  • Ö麣Á«»¨Â·
  • Ïà¹ØÍ¼Æ¬
  • ¹ðÁÖÀÏÏï×Ó
  • Á¹·Û̯
  • ÓͲè�
  • Ïà¹ØÍ¼Æ¬
  • ¹ðÁÖ¹ÊÊÂ

¡¶ÒË´º±£ÀûÊг¡µÄ¼¦½Ðɶ¡·

È«½·ÏØÒ¹°ë·¢Ìý֤֪ͨ £¬ÒÚ¾§¹âµçµÚ¶þÌ쿪Å̹ɼ۾ÍÌÉÆ½¡£±»µØ·½¹ú×Ê×·×ÅҪǮ £¬ÒÚ¾§¹âµç¿ÉÄÜÕÕ¾ÉÍ·Ò»¼Ò £¬µ«¿ÖŲ»ÊÇ×îºóÒ»¼Ò £¬Ö»ÊDzþâ±2025µÄÒ»¸öËõÓ°¡£

¡¶Ê¯¼ÒׯУ԰¼¦Í·ÔõôÕÒ¡·

2025Äê £¬FDA¹²Åú×¼Á½¿îеÄADCÒ©Îï¡£°üÀ¨£ºÓɰ¢Ë¹Àû¿µÓëµÚÒ»Èý¹²£¨Daiichi Sankyo£©ÁªºÏ¿ª·¢µÄTrop2°ÐÏòADCÁÆ·¨datopotamab deruxtecan £¬»ñÅúÓÃÓÚÖÎÁƾ­ÖÎHR+¡¢HER2-ÈéÏÙ°©»¼Õß £¬ÒÔ¼°Ð¯´øEGFRÍ»±äµÄNSCLC»¼Õß¡£°¬²®Î¬£¨AbbVie£©Ñз¢µÄc-Met°ÐÏòADCÁÆ·¨telisotuzumab vedotin£¨teliso-V£© £¬»ñÅúÓÃÓÚÖÎÁƾßÓиßc-MetÂѰ×Ì«¹ý±í´ïµÄ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔ¾­ÖηÇÁÛ×´NSCLC³ÉÄ껼Õß¡£

¡¶ËÕÖÝÄǸö³ÇÖдåÐ¡ÍÆÄÃ×ãÁÆÑøÉú¶àÄØ¡·

µÃÒæÓÚÓë¶Å¿ËÄÜÔ´¡¢ÄÏ·½µçÁ¦µÈ¹«ÓÃÊÂÒµ¹«Ë¾¸æ¿¢µÄÏàÖúЭÒé £¬EQT¹«Ë¾2024Äê6ÔÂͶÔ˵İ¢°ÍÀ­ÆõÑÇÉ½ÇøÊ䯸¹ÜµÀ £¬ÒÑѸËÙÌîÂúÁËÏÖÓÐÔËÁ¦¡£ÕâÁ½¼Ò¹«Ë¾¾ùÌåÏÖ £¬ÆäÔ¤¼ÆÐÂÔöµÄµçÁ¦¸ººÉÏÕЩȫ²¿À´×ÔÊý¾ÝÖÐÐÄ¡£¾¡¹ÜÕâÌõÈ«³¤303Ó¢ÀïµÄ¹ÜµÀÀúʱʮÄê²ÅµÃÒÔ½¨³ÉͶÔË £¬µ«EQT¹«Ë¾ÒÑÓÚÈ¥Äê»ñµÃÁª°îÕþ¸®Åú×¼ £¬½«¹ÜµÀÑÓÉìÖÁ±±¿¨ÂÞÀ´ÄÉÖÝ £¬¶Å¿ËÄÜÔ´Ò²ÒÑÌáǰԤ¶¨Á˹ܵÀÔËÁ¦¡£

ÍøÕ¾µØÍ¼